Bonraybio Co Ltd
Bonraybio Co Ltd is a biotechnology company focused on the development and commercialization of advanced medical equipment and technology, primarily generating revenue through product sales and research and development services.
Business. Bonraybio Co Ltd (6955.TW) is a healthcare company engaged in the advanced medical equipment and technology industry, primarily focused on healthcare equipment. The firm is listed on the Taiwan Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Bonraybio Co Ltd (6955.TW) is a healthcare company engaged in the advanced medical equipment and technology industry, primarily focused on healthcare equipment. The firm is listed on the Taiwan Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Bonraybio maintains a strong liquidity position, with a current ratio of 8.87, indicating that it holds significantly more current assets than current liabilities. The company's liquidity_fpt score is high, supported by a cash and equivalents balance of TWD 25.6 million and a free cash flow of TWD 15.5 million, which provides flexibility for operational and strategic initiatives.
Profitability metrics show a return on equity (ROE) of 4.93% and a return on assets (ROA) of 4.31%, which are below the industry median for biotechnology firms. However, the company's operating margin of 23.9% (calculated from operating income of TWD 11.5 million on revenue of TWD 48.2 million) suggests efficient cost management.
Geographically, Bonraybio's revenue is concentrated in a single disclosed segment, with no further breakdown provided in the available data. This lack of diversification may expose the company to regional market risks, particularly in the biotechnology sector where regulatory and demand dynamics can vary significantly.
The company's growth trajectory is modest, with no significant revenue growth reported in the latest period. Looking ahead, the outlook for the current fiscal year is stable, with no projected changes in revenue or operating income. The next fiscal year is also expected to remain flat, with no material changes in the business model or market conditions anticipated.
Risk factors for Bonraybio are currently low, with no immediate liquidity or dilution concerns identified. The company's debt-to-equity ratio of 0.04 indicates a conservative capital structure, and there are no signs of near-term equity dilution. However, the biotechnology industry is inherently research-intensive, and any significant R&D investment could impact future profitability.
Recent filings and transcripts do not highlight any material events or strategic shifts. The company's latest financial report, filed under standard disclosure protocols, shows consistent performance with no unexpected write-downs or restructuring charges. No earnings call transcripts are available for the most recent quarter, limiting insight into management's strategic outlook.
- Bonraybio maintains a strong liquidity position with a current ratio of 8.87 and TWD 25.6 million in cash and equivalents.
- The company's ROE of 4.93% and ROA of 4.31% are below industry medians, indicating room for improvement in asset utilization and profitability.
- Revenue is concentrated in a single segment, exposing the company to regional and market-specific risks.
- No immediate liquidity or dilution risks are present, and the capital structure is conservative with a debt-to-equity ratio of 0.04.
- Growth is expected to remain stable in the near term, with no significant changes in revenue or operating income projected.
Bull / Bear case
Generated · model-assistedRevenue grew 52.7% annually over four years, demonstrating strong top-line expansion momentum for the company.
Debt-to-equity ratio of 0.04 is lower than the cohort median of 0.06, reflecting a conservative capital structure.
Cash conversion ratio of 1.14 outperforms the cohort median of 0.79, highlighting strong cash generation capabilities.
Return on equity of 4.93% remains relatively low despite high profitability margins, suggesting inefficient capital utilization.
Return on invested capital of 3.81% indicates modest returns relative to the capital employed in operations.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Bonraybio Co Ltd Market data — financials · 2026-05-27